Eczema other diagnostic studies
|
Eczema Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Eczema On the Web |
|
American Roentgen Ray Society Images of Eczema |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Edzel Lorraine Co, D.M.D., M.D.
Overview
No particular biomarker is reliable to diagnose eczema. However, potential options include CD30, macrophage-derived chemoattractant (MDC}, thymus and activation-regulated cytokine (TARC), and interleukin-12 (IL-12) ,interleukin-16 (IL-16, interleukin-18 (IL-18), and interleukin-31 (IL-31).[1] [2] [3] [4]
Other Diagnostic Studies of Eczema
- No particular biomarker is reliable to diagnose eczema.
- However, potential options include:
- CD30
- Macrophage-derived chemoattractant (MDC)
- Thymus and activation-regulated cytokine (TARC)
- Interleukin-12 (IL-12)
- Interleukin-16 (IL-16)
- Interleukin-18 (IL-18)
- interleukin-31 (IL-31).
References
- ↑ Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL; et al. (2014). "Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis". J Am Acad Dermatol. 70 (2): 338–51. doi:10.1016/j.jaad.2013.10.010. PMC 4410183. PMID 24290431.
- ↑ Kabashima K (2013). "New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity". J Dermatol Sci. 70 (1): 3–11. doi:10.1016/j.jdermsci.2013.02.001. PMID 23473856.
- ↑ Murat-Susić S, Lipozencić J, Zizić V, Husar K, Marinović B (2006). "Serum eosinophil cationic protein in children with atopic dermatitis". Int J Dermatol. 45 (10): 1156–60. doi:10.1111/j.1365-4632.2006.02865.x. PMID 17040428.
- ↑ Schulte-Herbrüggen O, Fölster-Holst R, von Elstermann M, Augustin M, Hellweg R (2007). "Clinical relevance of nerve growth factor serum levels in patients with atopic dermatitis and psoriasis". Int Arch Allergy Immunol. 144 (3): 211–6. doi:10.1159/000103994. PMID 17579279.